FORGING NEW PATHS IN DIABETES MANAGEMENT
Now you can provide your patients with innovative CGM technology that can simplify their lives and provide better clinical outcomes. Eversense is the only CGM system with a 90-day, subcutaneous sensor – giving patients the longest wear time ever, along with unmatched convenience and accuracy.
90-days sensor wear
On-body vibe alerts
fully implantable sensor
4 sensor changes a year
vs. 26-52 for other CGM systems
Exceptional accuracy
Especially in the 40-60 mg/dl range
UNMET NEEDS IN CGM TECHNOLOGY CAN CAUSE PATIENTS TO STRUGGLE WITH WEAR-TIME GOALS
Patients with diabetes receive clinical benefit from continuous glucose monitoring when the sensor is worn more than 80% of the time.1,2
However, many patients struggle to meet this goal due to the limitations of traditional CGM technology:
- short sensor life
- accuracy issues
- difficulties with sensor self-insertion and removal
As a result, only
1 out of 3 type 1 diabetes patients are currently using CGM.3
1 out of 3 will discontinue use within a year.3
EVERSENSE DELIVERS UNMATCHED WEAR TIME AND IMPROVED GLYCEMIC OUTCOMES
The advanced sensor technology and under-the-skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.
With a 92% real-world wear time, Eversense exceeds both the 80% minimum threshold wear-time for clinical benefits and the 50-78% wear time for other CGMs.
92%
Eversense CGM
>80%
Required for optimal clinical benefit
57%
Traditional CGMs
Exceptional Accuracy
Highly accurate alert detection rates
Within a 15-minute window, the Eversense CGM System uses threshold and predictive alerts to detect:
of hypoglycemic events (70 mg/dL)
of hyperglycemic events(180 mg/dL)
In addition to visual and auditory alarms, Eversense’s unique predictive, on-body vibe alerts add an extra measure of safety, especially when patients are sleeping, or their mobile device is not close by.
Improved Clinical Outcomes
Multiple clinical trials have demonstrated that Eversense CGM use can reduce A1C levels.
READY TO GET STARTED AS A PROVIDER?
Ready to prescribe Eversense CGM? Just fill out a simple form with a few details and we will contact you to answer questions and get you started.
SENSOR
The 90-day fluorescent sensor is placed just under the skin in the upper arm and continuously measures glucose for up to 3 months.
Transmitter
Water-resistant, rechargeable and removable, the transmitter sends data in near-real time to the user’s mobile device, and also provides on-body vibration alerts during glycemic swings.
Mobile APP
Receives and displays glucose data in easy-to-read charts and graphs to show your patients if they are in or out of range. NO SEPARATE RECEIVER is required. Patients discreetly check their info on their personal iOS or Android mobile device or Apple Watch®.
